Symbiotec Pharmalab Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹280 Cr +37.9% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
SP

Symbiotec Pharmalab Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Symbiotec Pharmalab Q1 FY27: Revenue ₹218.2 Cr, EBITDA margin 21%

Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹218Cr
−11% QoQ
Net profit
₹14Cr
−50% QoQ
Margin
21%
−4 pp QoQ

Symbiotec Pharmalab Ltd Q1 FY27 key numbers

Revenue
API EBITDA increased 9% YoY to ₹65.8 crores, with ~30% EBITDA margin maintained.

As stated in Symbiotec Pharmalab Ltd's Q1 FY27 investor presentation · published 25 Sept 2026. Reported figures, not investment advice.

Based on Symbiotec Pharmalab Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹1,003
Market cap₹7.0K Cr
P/E61.0

The short version

Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Q1 FY27 EBITDA: Rs. 45.2 Cr, down from Rs. 58.0 Cr in Q1 FY26 (22% decline YoY).

From Symbiotec Pharmalab Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9).
  • API business revenue for Q1 FY27: ₹215.3 crores, up 6% YoY (Page 7).
  • Q1 FY27 gross margins at 65%, up 300 basis points YoY (Page 9).
  • API EBITDA increased 9% YoY to ₹65.8 crores, with ~30% EBITDA margin maintained (Page 7).
  • Management commentary projects API revenue growth expected to further pick up in subsequent quarters (Page 6).

2 more points from Symbiotec Pharmalab Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Symbiotec Pharmalab Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Total gross capex invested as of June 30, 2026: ₹1,475 Cr; estimated total by end FY27: ₹1,666 Cr.
  • API (Steroids & Hormones): ₹644 Cr invested; fully generating revenue; asset turns ~1.5X.
  • Complex Injectables (Dual Chamber Vials - DCV): ₹356 Cr invested (₹376 Cr est.); majority capacity reserved with strategic partner.
  • Biotech CDMO Services (400 KL + 14 KL): ₹471 Cr invested (₹584 Cr est.); backed by take-or-pay customer agreements.
  • New API Capex: ₹4 Cr invested, estimated ₹63 Cr total; currently in discussions.
  • New biologics facility (14 KL) at Ujjain under construction.
  • Biotech plant expansion at SEZ Pithampur (280 KL) commissioned; biomanufacturing facility at Ujjain (400 KL) commissioned.
  • 600 KL new CDMO capacities to be initiated, backed by customer agreement, revenue to commence in next 6–12 months.

2 more points from Symbiotec Pharmalab Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Symbiotec Pharmalab Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Symbiotec Pharmalab Ltd said on order book & pipeline — free account, 30 seconds.

Symbiotec Pharmalab Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Symbiotec Pharmalab Ltd Q1 FY27 results — key figures

Symbiotec Pharmalab Ltd Q1 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ1 FY27Q4 FY26QoQ
Revenue218245-11%
Operating profit (EBITDA)4562-27.4%
Operating margin21%25%-4 pp
Profit before tax1835-48.6%
Net profit (PAT)1428-50%
EPS (₹)2.244.39-49%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹280 Cr, net profit ₹52 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Symbiotec Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Symbiotec Pharmalab Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Symbiotec Pharmalab Ltd Q1 FY27 results?

Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Q1 FY27 EBITDA: Rs. 45.2 Cr, down from Rs. 58.0 Cr in Q1 FY26 (22% decline YoY).

What is Symbiotec Pharmalab Ltd share price analysis?

Symbiotec Pharmalab Ltd currently shows a neutral. The stock trades at a P/E of 61.0 with a market cap of ₹7,037 Cr. Investors should review the full earnings analysis for detailed insights.

Is Symbiotec Pharmalab Ltd planning capital expenditure?

Total gross capex invested as of June 30, 2026: ₹1,475 Cr; estimated total by end FY27: ₹1,666 Cr.

Keep Symbiotec Pharmalab Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.